CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer

摘要: CPT-11 (irinotecan) has shown activity in patients with advanced colorectal cancer resistant to leucovorin (LV) and 5-fluorouracil (5-FU). In this study, the simplified bimonthly LV-5-FU regimen was combined (FOLFIRI) as third-line therapy for cancer. Continuous infusion of 5-FU administered disposable pumps outpatient therapy. FOLFIRI consisted 180 mg/m2 a 90-min day 1; LV 400 2-h during CPT-11, immediately followed by bolus 46-h continuous 2.4-3 g/m2 every 2 weeks. Among 33 treated, had partial responses an overall response rate 6%; 20 were stabilised (61%) 11 disease progression (33%). From start FOLFIRI, median progression-free survival 18 weeks 43 For 242 cycles analysed, NCI-CTC toxicities grade 3-4 per patient nausea 15%, diarrhoea 12% neutropenia 15%. Overall, 10 (30%) experienced toxicity. 7 (21%) alopecia. generated acceptable toxicity, heavily pretreated patients, limited diarrhoea, mostly asymptomatic manageable relatively uncommon This is suitable studies chemotherapy-naive patients.